We thus aimed to generate an ADC targeting MICA/B- expressing tumors with a dual function to achieve optimal therapeutic benefits: (i) killing of tumor cells and (ii) disrupting the interaction between MICA/B and NKG2D that induces impaired immunosurveillance [1] [2]. The gene discussed is KLRK1; the disease is neoplasm.